Trends in hospitalisations for lower respiratory tract infection

2 after the COVID-19 pandemic in adults with chronic respiratory

disease

4 Alexandre Sabaté-Elabbadi^{1,2}, Lucie Brolon^{1,2}, Christian Brun-Buisson^{1,2}, Didier
5 Guillemot^{1,2,3}, Muriel Fartoukh⁴, Laurence Watier^{1,2}

6 Authors Affiliation:

3

7 ⁽¹⁾ Université Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut

8 National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en

9 Epidémiologie et Santé des Populations (CESP), Anti-infective evasion and

10 pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France

11 ⁽²⁾ Institut Pasteur, Université Paris-Cité, Epidemiology and Modelling of Antimicrobials

- 12 Evasion (EMAE), Paris, France
- 13 ⁽³⁾ Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris (AP-HP), Public Health,
- 14 Medical Information, Clinical Research, Le Kremlin-Bicêtre, France

15 (4) Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Service de

- 16 Médecine Intensive Réanimation, Hôpital Tenon, Paris, France
- 17 Authors' Contributions

18 LW, MF, CBB and ASE are responsible for the conception and design of the study. ASE, LW

19 and LB collected the data and participated in the statistical analysis. ASE drafted the

20 manuscript. LW, MF, DG and CBB critically revised the manuscript. All the authors read and

21 approved the final manuscript.

- 22 Corresponding Author: Alexandre Sabaté-Elabbadi, Epidemiology and Modelling of
- 23 Antimicrobials Evasion (EMAE), Institut Pasteur, 25-28 rue du Dr Roux, 75015 Paris, France
- 24 Email: <u>alexandre.elabbadi@pasteur.fr</u>.
- 25 ORCID iD: <u>https://orcid.org/0000-0003-1103-1040</u>
- 26 Keywords: Lower respiratory tract infection; Coronavirus disease 2019; Chronic respiratory
- 27 disease; Nationwide study; French National Hospital Discharge Database
- 28 Main text word count: 3275 words

29 ABSTRACT

Introduction: COVID-19 pandemic has modified the epidemiology of lower respiratory tract infections (LRTI), particularly in patients presenting a chronic respiratory disease (CRD). LRTI incidence substantially decreased at the start of the COVID-19 pandemic. However, studies focusing on the post-pandemic period are missing. We aimed to evaluate the impact of the pandemic and post-pandemic periods on hospital admissions for LRTI, with a focus on patients with CRD.

Methods: From July 2013 to June 2023, monthly numbers of adult hospitalisations for LRTI (excluding SARS-CoV-2) were extracted from the anonymized French National Hospital Discharge Database. They were modelled by regressions with autocorrelated errors. Three periods were defined: (1) early pandemic and successive lockdowns (April 2020 to May 2021); (2) gradual lifting of restrictions and widespread SARS-CoV-2 vaccination (June 2021 to June 2022); (3) withdrawal of restriction measures (July 2022 to July 2023). Analyses were computed for the entire series, by gender, age, severity, and pre-existing CRD

43 **Results:** Before the pandemic, LRTI hospitalisations showed a winter seasonal pattern with a 44 rising trend. Pre-pandemic incidence was 96 (90.5 to 101.5) per 100,000 population. 45 Compared with the pre-pandemic period, seasonality was no longer present and significant 46 reductions were estimated in the first two periods: -43.64% (-50.11 to -37.17) and -32.97% (-47 39.88 to -26.05), respectively. A rebound with a positive trend and a seasonal pattern was 48 observed in period 3. Similar results were observed for CRD patients with no significant 49 difference with pre-pandemic levels in the last period (-9.21%; -20.9% to 1.67%), albeit with 50 differential changes according to the type of CRD.

Conclusions: COVID-19 pandemic containment measures contributed to significant changes
 in LRTI incidence, with a rapid increase and return to a seasonal pattern after their gradual
 lifting, particularly in patients with CRD.

54 Abstract word count: 286 words

55 INTRODUCTION

56 Community-acquired lower respiratory tract infections (LRTI) encompass heterogeneous 57 conditions of community onset, including community-acquired pneumonia (CAP), and other 58 respiratory tract infections (acute bronchitis, acute exacerbation of chronic obstructive 59 pulmonary disease (COPD), acute exacerbation of bronchiectasis) (1). LRTI remain the major cause of death from infectious diseases worldwide (2). In Europe, the burden is substantial 60 61 with an incidence of 1.5 per 1,000 inhabitants, and the economic impact is considerable, with 62 an estimated annual cost in Europe of 10 billion Euros (3). In addition, patients with chronic 63 respiratory disease (CRD) are particularly at risk of respiratory infection (4,5), and related 64 mortality (6).

The public health measures implemented in many countries to contain COVID-19 pandemic led to a substantial drop in hospitalisations for other causes of LRTI (7,8). This decline was partly driven by a decrease in the circulation of seasonal respiratory viruses (8,9), but also by a concomitant reduction in the number of bacterial infections associated with microorganisms usually involved in LRTI (10). This reduction in hospital admissions for LRTI was also observed in patients with CRD (11,12), as respiratory viruses are known to contribute significantly to CRD exacerbations in this population (13).

72 In France, as in many European countries, non-pharmaceutical interventions (NPI) varied 73 during the pandemic (14); with particularly strict measures in 2020 until the spring of 2021, 74 then a gradual relaxation of these measures until August 2022 when they were totally 75 withdrawn (15). Data suggest that gradual easing of NPI has been accompanied by a 76 resurgence in respiratory-transmitted viruses (16), notably respiratory syncytial virus (RSV) (17). However, studies analysing the overall changes in hospitalisations for LRTI associated 77 78 with these NPI and their lifting during and after the pandemic, are lacking, particularly in 79 patients with CRD. Moreover, if COVID-19 is evolving into a seasonal pattern as research

suggests (18), it is crucial to gather data on its post-pandemic impact on the overall LRTI
burden.

We aimed to assess and quantify the impact of the pandemic on the trend of hospitalisations for LRTI and the characteristics and severity of inpatients, both overall and among those with a preexisting CRD, during and after the pandemic.

85 **METHODS**

86 Study population and selection of hospital stays with LRTI

87 Hospitalisations of patients aged > 15 years with LRTI (excluding SARS-CoV-2) in 88 metropolitan France from July 2013 to June 2023 were extracted and aggregated monthly, 89 from the French National Hospital Discharge Database (PMSI: Programme de Médicalisation 90 des Sytèmes d'Informations) (19). LRTI was defined by the presence of a related ICD-10 91 code during hospital stay. Rates of hospitalisations per 100,000 inhabitants and per month 92 were calculated, taking into account the French population growth. For each stay, gender, age, 93 type (acute pneumonia, acute bronchitis, acute exacerbation of COPD, acute exacerbation of 94 bronchiectasis) and severity of LRTI (moderate, severe, and death) (20), were also extracted. 95 Presence of a CRD was defined by an ICD-10 code during the hospital stay. For more details 96 on population selection, see **Table S1-3**, **Supplementary data**. We then classified the CRD 97 into 8 non-exclusive categories representing the main CRD: (i) COPD, (ii) Asthma, (iii) 98 Cystic Fibrosis and other bronchiectasis (CF-Bronchiectasis), (iv) interstitial lung disease 99 (ILD), (v) thoracic oncology, (vi) pulmonary vascular disease (PVD), (vii) CRD associated 100 with neuromuscular disease (CRD-NM), and (viii) lung transplantation. 101 Finally, we also considered monthly numbers of hospitalisations with LRTI including SARS-

102 CoV-2 in the last period (i.e. without restriction measures).

103 Ethics Statement

- 104 As this was a retrospective study of an anonymized database, ethics committee approval was
- 105 not required, as per French law. The study was conducted using the Institut National de la
- 106 Santé et de la Recherche Médicale permanent access to the the French National Hospital
- 107 Discharge Database (PMSI).

108 Statistical analyses

109 To study the impact of the pandemic periods on changes in hospitalisations rates for LRTI, 110 segmented regression models with autocorrelated errors were used (21). Three periods were 111 defined: the first covers the start of the pandemic in France, including 3 successive lockdowns 112 (April 2020 to May 2021); the second covers the gradual removal of restrictions and the 113 widespread COVID-19 vaccination (June 2021 to June 2022); and the last, extending from 114 July 2022 to July 2023, covers the last epidemic season without restriction measures (Table 115 **S4**, **Supplementary data**). For each period, a regression line with a trigonometric function, if 116 the series exhibited annual seasonality, was estimated. If non-significant, the slope was 117 removed. We quantified the estimated difference in incidence and percent changes of monthly 118 rates of hospitalisations for each intervention, as compared with the pre-pandemic period, by 119 calculating the difference between the monthly estimated incidence predicted by the model 120 and the one expected under the assumption of no change since the pre-pandemic period. More 121 details are available in **Supplementary data**.

122 Analyses were performed for LRTI excluding SARS-CoV-2, by age group (15 to 54, 55 to 64,

123 65 to 74 and >75 years), gender, type of LRTI (classified as pneumonia or other types of

- 124 LRTI), severity, and presence of a CRD. A final analysis was related to the LRTI series
- 125 including SARS-CoV-2 in the last period.
- 126 Statistical analyses were computed with SAS[®] Enterprise Guide (Version 8.3; SAS Institute
- 127 Inc., Cary NC, USA) and R (Version 4.3.2; R Core Team, Vienna, Austria, 2023).

128 **RESULTS**

Between July 2013 and June 2023, 5,339,989 in-hospital stays for LRTI were identified (**Table 1**). Their median [Q1-Q3] age was 78 [65-87] years, and women accounted for 44.9% of inpatients. Overall, one third of patients (34.5%) had at least one CRD, mainly COPD

(19.4%). Almost 25% of patients were admitted to the ICU during their hospital stay, 60.5%
of whom directly. The median hospital length of stay was 9 [5-15] days, and 729,568 (13.7%)
patients died.

135 Overall, the age of patients hospitalised decreased after the onset of the pandemic and 136 remained stable thereafter: 79 [65-87] years in pre-COVID period and around 76 [64-86] 137 years for the 3 periods. The proportion of women decreased after the start of the pandemic, 138 followed by an increase in periods 2 and 3. Similarly, in period 1, there was a drop in the 139 proportion of patients with CRD (33.8% versus 34.5% in pre-pandemic period), mainly due to 140 a reduction in COPD and asthma. In addition, the number of deaths increased during the early 141 stages of the pandemic from 13.1% to 16.3% at period 1, as did the number of ICU 142 admissions (23.6% to 25.5%). Noteworthy, mortality among patients admitted to the ICU 143 increased from 20.8% to 22% during period 1. Overall, 20.9% of patients with an ICU stay 144 died over the entire study period.

A segmented regression model with autocorrelated error fulfilling goodness-of-fit criteria was obtained for each series (**Figure 1 and Figures S1-2, 4-6, 8-9, Supplementary data**). The estimated differences in monthly rates of hospitalisations per 100,000 inhabitants during the periods are reported for all the considered series in **Table S5 (Supplementary data**) (in incidence rates) and **Figures 2 and Figure S3 in Supplementary data** (in percent change relative to the pre-pandemic period).

Monthly rate of hospitalisations for LRTI showed a winter seasonal pattern in the adult population during the pre-pandemic period, with a rising trend from 2013 to 2020 (**Figure 1A**). Compared with the pre-pandemic period, a significant decrease in LRTI hospitalisations was observed in the early period 1 (-43.6%; 95% CI: -50.1% to -37.2%. **Figure 2A**). This decline was associated with a loss of the seasonality pattern and slope. Compared with the pre-pandemic period, the decrease was maintained but less marked during period 2 (-33.0%;

157 95% CI: -39.9% to -26.1%), and even less pronounced during period 3 (-18.5%; 95% CI: -158 29.2% to -7.9%). This was also associated with a significantly higher slope than in the pre-159 pandemic period (+2.3; 95% CI: 0.2 to 4.4; p=0.04) and a return to the seasonal pattern seen 160 previously (Figure 1A). The same overall tendency occurred in the presence of at least one 161 CRD, with a significant decrease in LRTI hospitalisations when successive lockdown and 162 strict NPI measures were implemented, followed by a gradual increase at periods 2 and 3 163 (Figures 1B and 2A). Notably, during period 3, there was a resurgence of seasonality and an 164 upward slope (+0.7; 95% CI: +0.1 to +1.4; p=0.04). Furthermore, this trend had almost 165 returned to the pre-pandemic level during period 3 and was not statistically different (-9.2%; 166 95% CI: -20.9% to 1.7%). It should be noted that this reduction of hospitalisations in CRD 167 inpatients was less pronounced than in those without CRD (Figures 1C and 2A).

168 Focusing on the different categories of CRD, the drop of LRTI hospitalisations involved all 169 respiratory diseases during period 1 (Figure 2B and Figure S1, Supplementary data), and 170 particularly asthma (-53.4%; 95% CI: -60.3% to -46.5%) and COPD (-41.8%; 95% CI: -171 49.0% to -34.6%). At periods 2 and 3, there was a gradual reduction of these differences in all 172 categories of CRD. Altogether, at period 3, the average level of LRTI hospitalisations did not 173 return to the pre-pandemic level for COPD (-14.8%; 95% CI: -25.5% to -4.1%), 174 CF/bronchiectasis (-22.0%; 95% CI: -33.8% to -10.2%), thoracic oncology (-13.9%; 95% CI: 175 -19.3% to -8.6%), lung transplantation (-19.9%; 95% CI: -26.9% to -12.8%) and CRD 176 associated with NMD (-18.8%; 95% CI: -27.8% to -9.8%) (Figure S1, Supplementary 177 data). Conversely, this difference was no longer significant for asthma (-4.1%; 95% CI: -178 16.8% to +8.7%) and ILD (-3.1%; 95% CI: -16.5% to +10.4%), as compared with the pre-179 pandemic period.

180 The decline in LRTI hospitalisations was more pronounced for moderately severe LRTI, as 181 compared with severe LRTI and those associated with death (**Figures S2 and S3A**,

Supplementary data). In addition, moderate forms showed a significant upward trend during
study period 3 (+1.8; 95% CI: +0.2 to +3.3; p=0.03), a trend not seen in the two other forms
(Table S6 and Figure S3A, Supplementary data). Notably, at period 3, the decrease in
LRTI hospitalisations did not differ from that of the pre-pandemic period for the episodes
associated with death (-2.2%; 95% CI: -10.9% to +6.4%).
Focusing on pneumonia, a sharper decline occurred during period 1 (-36.3%; 95% CI: -42.9%
to -29.7%) than period 2 (-27.6%; 95% CI: -34.3% to -21.0%) (Figures S3B and S4A,

Supplementary data). In period 3, there was a lower but still significant decrease (-13.3%;
95% CI: -22.9% to -3.8%). For other types of LRTI, more pronounced trends were observed
with a respective decrease of 56.6% (95% CI: -68.4% to -44.7%) at period 1, 45.7% (95% CI:
-58.1% to -33.4%) at period 2 and 32.7% (95% CI: -45.6% to -19.9%) at period 3 (Figure
S3B and S4B, Supplementary data). Moreover, unlike pneumonia, there was no increasing
slope during period 3, although there was a seasonality pattern.

Although the decline in hospitalisations was greater among women, there was a marked decrease in period 1 in both genders. This change was gradually less important during periods 2 and 3 compared to the pre-pandemic period (**Figure S3C and Figure S5, Supplementary data**). This feature was similar for all age categories studied, although the decline was greatest among oldest patients (i.e., over 75 years) (**Figure S3D and S6, Supplementary data**).

201 Concurrent with the increase in LRTI hospitalisations, the proportion of COVID-19 202 hospitalisations among all LRTI decreased from period 1 to period 3 (**Figure S7**, 203 **Supplementary data**). During period 1, they accounted for nearly half of all respiratory 204 infections hospitalised, dropping to one-third during period 2, and less than 20% during the 205 last epidemic season despite the reduction of NPI (**Table S7**, **Supplementary data**). 206 Interestingly, COVID-19 hospitalisations exhibited a winter seasonality comparable to other

207	hospitalised LRTI at period 3. In this context, when comparing period 3 with the pre-
208	pandemic period, the overall burden of hospitalisations for LRTI, (including COVID-19), is
209	comparable to that of the pre-pandemic period (+0.3; 95% CI: -9.0% to +9.7%) (Figure S8
210	and Table S6, Supplementary data). Notably, when a CRD is present, the increase in
211	hospitalisations is more important at period 3 compared with the predicted level (Figure S9,
212	Supplementary data), but not statistically significant: + 6.1% (95% CI: -3.4% to +15.7%)

213 versus +1.0% (95% CI-8.9% to +11.0%) if no CRD is present.

214 DISCUSSION

In this nationwide study using The French National Hospital Discharge Database, we showed a marked decrease of hospital admissions for LRTI unrelated to COVID-19 at the onset of the pandemic, followed by a subsequent rise coinciding with the lifting of COVID-19 control measures and a return to a seasonal pattern, particularly notable in patients with CRD. This increase in LRTI hospitalisations was associated with a return to pre-pandemic levels within this group, with some discrepancies depending on the type of CRD.

221 Our findings document the significant decline in hospital admissions for LRTI unrelated to 222 COVID-19 when NPI measures were implemented to control the pandemic. This trend has 223 been well documented in the literature, as these measures reduced the circulation of 224 respiratory viruses (22–24), as well as some bacteria typically associated with LRTI (10,25). 225 Following the partial relaxation and eventual complete lifting of COVID-19 control measures, 226 a notable resurgence in hospitalisations for other LRTI was observed. This trend has been 227 previously demonstrated, specifically in the paediatric population, and coincided with the 228 sustained resurgence of the RSV epidemic (26). While post-pandemic COVID-19 data in the 229 adult population are lacking, several studies have indicated an increase in the incidence of 230 other LRTI following the easing of restrictions (23,27,28). Our study further contributes to

231 this understanding, highlighting that this increase is not only important when NPI are relaxed, 232 but also follows a typical winter seasonal pattern consistent with pre-pandemic trends, 233 underlining the role of seasonal viruses. Community-acquired pneumonia exhibited a lesser 234 reduction in hospitalisations compared to non-pneumonic LRTI, such as exacerbations of 235 COPD, bronchiolitis, and acute bronchitis. Pneumonia is indeed recognized as the primary 236 cause of hospitalisations among all LRTI (29). The frequent involvement of respiratory 237 viruses during acute bronchitis (30) and acute exacerbations of COPD (31) may have been 238 particularly affected by NPI. However, during the period when NPI were completely lifted, 239 the resurgence of non-pneumonic LRTI was less significant than that of pneumonia. This 240 could be attributed to an increased focus on outpatient management of non-pneumonic LRTI 241 during and extending after the pandemic. Furthermore, the continued adherence to some NPI 242 by vulnerable populations (32) and health professionals (33) may have contributed to 243 mitigating the increase in LRTI incidence beyond the pandemic.

244 Changes in hospital admissions for LRTI were primarily driven by mild-to-moderately severe 245 forms of LRTI. Indeed, our findings indicate that the decrease in episodes of LRTI leading to 246 ICU admission or death was less pronounced than that observed for mild-to-moderately 247 severe forms of LRTI. It can be assumed that some of the latter cases were managed through 248 outpatient care or required fewer medical consultations (34,35). Additionally, while the 249 overall level of LRTI hospitalisations may not be entirely comparable to that of the pre-250 pandemic period, the rate of fatal LRTI episodes remained similar. This suggests that the 251 criteria for hospitalisation for LRTI may have been more stringent and that hospitalised 252 patients may have been more severe.

We found that patients with CRD accounted for 30% of all LRTI inpatients, with half of them diagnosed with COPD. Our findings underscore the significant impact of NPI on patients with CRD, demonstrating a substantial decrease in hospitalisations for LRTI during the most

256 restrictive NPI period, followed by a subsequent rise during the relaxation phases. 257 Interestingly, a return to pre-pandemic levels was observed in CRD patients upon complete 258 lifting of restrictions. This observation is particularly interesting as it highlights the 259 vulnerability of this population to LRTI, while also emphasizing the critical role of NPI in 260 mitigating the burden of LRTI among CRD individuals (23,36). This observation may be 261 partly supported by a reduction in the circulation of respiratory viruses during the pandemic, a 262 factor well-documented to trigger CRD exacerbations, notably asthma and COPD (23). 263 Indeed, we observed the most significant initial decline in hospitalisations for these two 264 populations. Moreover, we noted a return to pre-pandemic levels among hospitalised asthma 265 patients. In contrast, for COPD patients, who accounted for more than half of CRD 266 hospitalisations for LRTI, a notable increase was observed after removal of NPI, although it 267 did not reach pre-pandemic levels. One possible explanation for this partial return to pre-268 pandemic levels might be an ongoing adherence to protective measures, such as wearing 269 masks in the community and systematic hand washing (37). Interestingly, patients with ILD 270 experienced a significant increase in hospitalisations following the lifting of NPIs, returning 271 to pre-pandemic levels. LRTI account for approximately 20% of admissions in these patients 272 (38) and may worsen their condition (39), emphasizing the importance of maintaining NPI 273 measures in this population.

Following the complete release of NPI, COVID-19 still accounted for 20% of hospitalised LRTI, and exhibited an epidemic pattern overlapping with other LRTI, highlighting the propensity for SARS-CoV-2 to become seasonal (18). Despite variations in the pathogens involved, the overall level of LRTIs in period 3 did not significantly surpass pre-pandemic levels, indicating that the simultaneous occurrence of multiple respiratory pathogen epidemics did not lead to an excessive increase in hospitalisations for LRTIs in France. Finally, it is noteworthy that CRD patients experienced a more significant increase, highlighting the

particularly vulnerability of this population to respiratory pathogens, including COVID-19(40).

283 Our study has several strengths. Firstly, it utilizes national data encompassing all 284 hospitalisations in France over a 10-year period. Secondly, the study period covers a complete 285 epidemic season after the end of all NPI recommendations, allowing an examination of 286 overall trends in hospitalisations for LRTI. Moreover, our approach provides an estimate of 287 the burden of LRTI in patients with CRD at the national level post-pandemic. Identifying key 288 interventions for LRTI control and prospectively demonstrating which of these are most 289 acceptable and easily followed by vulnerable populations, such as CRD patients, could be 290 effective in reducing the burden of these conditions on hospitals. While implementing all NPI 291 measures like lockdowns may not be feasible or acceptable, some could be beneficial, 292 particularly among patients with CRD. For example, measures such as mask-wearing have 293 been shown to have a real impact on reducing the circulation of certain viruses such as RSV 294 (22). Moreover, some of these less restrictive measures appear to be adhered to among 295 patients with CRD (32,37). Therefore, targeted implementation of specific NPI on vulnerable 296 populations (i.e., CRD, as well as older individuals) could be considered as a viable strategy 297 for mitigating the burden of respiratory infections.

298 Our study presents limitations. Although our study suggests that the lifting of NPI impacts 299 hospital admissions for LRTI, we were unable to determine which measures have the most 300 significant impact. Furthermore, this is an observational study investigating the temporal 301 relationship between hospitalisations for LRTI and NPI, but we cannot establish a strict 302 correlation and cannot exclude the possibility that other factors may have influenced these 303 variations. Moreover, medico-administrative databases have restricted access to clinical data, 304 which limits the accuracy of our diagnoses. This limitation is inherent to such databases, and 305 we utilized ICD-10 codes commonly used for research in these disease categories.

306	Nevertheless.	the French	public health	insurance system	regularly	audits and	randomly	/ checks

- that coding records correspond to actual patient records, thereby reducing coding errors (41).
- 308 Finally, due to imperfect pathogen coding in these databases, with many LRTI remaining
- 309 unidentified, we could only study LRTI collectively.
- 310 Our study emphasizes that the lifting of restrictions is associated with a rapid return to the
- 311 typical seasonality of LRTI. Hospitalisations for LRTI among patients with CRD returned to
- 312 pre-pandemic levels. Finally, given the persistent circulation of COVID-19, its influence on
- 313 hospitalisations remains significant.
- 314

315 Aknowledgment

- 316 The authors thank Bérénice Varga for her careful revision of the manuscript.
- 317 Funding information
- 318 Doctoral fellowship was received by ASE from Université Paris-Saclay. The funder has no
- role in the conceptualization, design, data collection, analysis, decision to publish, orpreparation of the manuscript.
- 321 Competing Interests

ASE reports support for attending meeting from SOS Oxygène and LVL Medical outside the submitted work. MF reports grants from BioMérieux and personal fees from BioMérieux, Pfizer, SOS Oxygène and Fisher and Paykel outside the submitted work. LW reports personal fees from Pfizer, Sanofi and Heva outside the submitted work. DG, CBB and LB have no competing interests to declare.

328 **REFERENCES**

- 329 1. Woodhead M. New guidelines for the management of adult lower respiratory tract
- infections. Eur Respir J. 1 déc 2011;38(6):1250□1.
- 2. Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SRM, et al. Estimates of the
- 332 global, regional, and national morbidity, mortality, and aetiologies of lower respiratory
- infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of
- 334 Disease Study 2016. Lancet Infect Dis. nov 2018;18(11):1191 210.
- 335 3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired
 pneumonia among adults in Europe. Thorax. janv 2012;67(1):71 9.
- 4. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults
- 338 Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and
- 339 Mortality. Clin Infect Dis. 13 nov 2017;65(11):1806 12.
- 340 5. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired
- 341 pneumonia in adults in Europe: a literature review. Thorax. nov $2013;68(11):1057 \square 65$.
- 342 6. Restrepo MI. COPD is associated with increased mortality in patients with community-
- acquired pneumonia. Eur Respir J. 1 août $2006;28(2):346 \square 51$.
- 344 7. Huh K, Jung J, Hong J, Kim M, Ahn JG, Kim JH, et al. Impact of Nonpharmaceutical
- 345 Interventions on the Incidence of Respiratory Infections During the Coronavirus Disease
- 346 2019 (COVID-19) Outbreak in Korea: A Nationwide Surveillance Study. Clin Infect Dis.
- 347 8 avr 2021;72(7):e184□91.
- Sakamoto H, Ishikane M, Ueda P. Seasonal Influenza Activity During the SARS-CoV-2
 Outbreak in Japan. JAMA. 19 mai 2020;323(19):1969.
- 350 9. Poole S, Brendish NJ, Clark TW. SARS-CoV-2 has displaced other seasonal respiratory
- viruses: Results from a prospective cohort study. J Infect. déc 2020;81(6):966 □72.

- 10. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden
- 353 MCJ, et al. Changes in the incidence of invasive disease due to Streptococcus
- 354 pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19
- 355 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance
- 356 Initiative: a prospective analysis of surveillance data. Lancet Digit Health. juin
- 357 2021;3(6):e360□70.
- 11. Huh K, Kim YE, Ji W, Kim DW, Lee EJ, Kim JH, et al. Decrease in hospital admissions
- for respiratory diseases during the COVID-19 pandemic: a nationwide claims study.
- 360 Thorax. sept $2021;76(9):939 \square 41$.
- 12. Shah SA, Quint JK, Nwaru BI, Sheikh A. Impact of COVID-19 national lockdown on
- 362 asthma exacerbations: interrupted time-series analysis of English primary care data.
- 363 Thorax. sept 2021;76(9):860□6.
- 364 13. Mallia P, Johnston SL. How Viral Infections Cause Exacerbation of Airway Diseases.
 365 Chest. oct 2006;130(4):1203
 10.
- 366 14. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel
- 367 database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat
- 368 Hum Behav. 8 mars 2021;5(4):529 38.
- 369 15. gouvernement.fr [Internet]. 2022 [cité 30 nov 2023]. Covid-19□: fin du «□ pass
- 370 sanitaire \square » le 1er août 2022. Disponible sur:
- 371 https://www.gouvernement.fr/actualite/covid-19-fin-du-pass-sanitaire-le-1er-aout-2022
- 16. Launay T, Souty C, Vilcu AM, Turbelin C, Blanchon T, Guerrisi C, et al. Common
- 373 communicable diseases in the general population in France during the COVID-19
- 374 pandemic. Shaman J, éditeur. PLOS ONE. 11 oct 2021;16(10):e0258391.

- 17. Fourgeaud J, Toubiana J, Chappuy H, Delacourt C, Moulin F, Parize P, et al. Impact of
- public health measures on the post-COVID-19 respiratory syncytial virus epidemics in
- France. Eur J Clin Microbiol Infect Dis. nov $2021;40(11):2389 \square 95$.
- 18. Wiemken TL, Khan F, Puzniak L, Yang W, Simmering J, Polgreen P, et al. Seasonal
- trends in COVID-19 cases, hospitalizations, and mortality in the United States and
- 380 Europe. Sci Rep. 8 mars 2023;13(1):3886.
- 381 19. ATIH. : Rapport d'activité ATIH 2021 [Internet]. ATIH; 2021. Disponible sur:
- 382 https://www.atih.sante.fr/sites/default/files/public/content/2196/rapport_dactivite_atih_20
- 383 21_1.pdf
- 384 20. Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al.
- 385 ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-

acquired pneumonia. Eur Respir J. avr 2023;61(4):2200735.

- 387 21. Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the
- evaluation of public health interventions: a tutorial. Int J Epidemiol. 9 juin 2016;dyw098.
- 389 22. Lenglart L, Ouldali N, Honeyford K, Bognar Z, Bressan S, Buonsenso D, et al.
- 390 Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an
- 391 interrupted time-series analysis based on a multinational surveillance system. Eur Respir
- 392 J. févr 2023;61(2):2201172.
- 393 23. Ho T, Shahzad A, Jones A, Raghavan N, Loeb M, Johnston N. Examining the effect of
- the COVID-19 pandemic on community virus prevalence and healthcare utilisation
- 395 reveals that peaks in asthma, COPD and respiratory tract infection occur with the re-
- emergence of rhino/enterovirus. Thorax. déc $2023;78(12):1248 \square 53$.
- 397 24. Partridge E, McCleery E, Cheema R, Nakra N, Lakshminrusimha S, Tancredi DJ, et al.
- 398 Evaluation of Seasonal Respiratory Virus Activity Before and After the Statewide

399 COVID-19 Shelter-in-Place Order in Northern California. JAMA Netw Oper	. 25 janv
--	-----------

400 2021;4(1):e2035281.

- 401 25. Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, et al.
- 402 Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results
- 403 of a global survey, 2017 to 2021. Eurosurveillance [Internet]. 12 mai 2022 [cité 7 févr
- 404 2024];27(19). Disponible sur: https://www.eurosurveillance.org/content/10.2807/1560-
- 405 7917.ES.2022.27.19.2100746
- 406 26. Bardsley M, Morbey RA, Hughes HE, Beck CR, Watson CH, Zhao H, et al.
- 407 Epidemiology of respiratory syncytial virus in children younger than 5 years in England
- 408 during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic
- 409 surveillance: a retrospective observational study. Lancet Infect Dis. janv

410 2023;23(1):56 66.

411 27. Zuo Z, Yang C, Ye F, Wang M, Wu J, Tao C, et al. Trends in respiratory diseases before

412 and after the COVID-19 pandemic in China from 2010 to 2021. BMC Public Health. 1

413 févr 2023;23(1):217.

414 28. Guadalupe-Fernández V, Martínez-Solanas E, Sabrià-Sunyé A, Ferrer-Mikoly C,

415 Martínez-Mateo A, Ciruela-Navas P, et al. Investigating epidemiological distribution

- 416 (temporality and intensity) of respiratory pathogens following COVID-19 de-escalation
- 417 process in Catalonia, September 2016–June 2021: Analysis of regional surveillance data.

418 González-Domenech CM, éditeur. PLOS ONE. 9 févr 2024;19(2):e0285892.

- 419 29. Schaberg T, Gialdroni-Grassi G, Huchon G, Leophonte P, Manresa F, Woodhead M. An
- 420 analysis of decisions by European general practitioners to admit to hospital patients with
- 421 lower respiratory tract infections. The European Study Group of Community Acquired
- 422 Pneumonia (ESOCAP) of the European Respiratory Society. Thorax. 1 oct
- 423 1996;51(10):1017 22.

- 424 30. Macfarlane J. Prospective study of the incidence, aetiology and outcome of adult lower
- respiratory tract illness in the community. Thorax. 1 févr 2001;56(2):109□14.
- 426 31. Zwaans WAR, Mallia P, Van Winden MEC, Rohde GGU. The relevance of respiratory
- 427 viral infections in the exacerbations of chronic obstructive pulmonary disease—A
- 428 systematic review. J Clin Virol. oct $2014;61(2):181 \square 8$.
- 429 32. Hurst JR, Cumella A, Niklewicz CN, Philip KEJ, Singh V, Hopkinson NS. Acceptability
- 430 of hygiene, face covering and social distancing interventions to prevent exacerbations in
- 431 people living with airways diseases. Thorax. mai $2022;77(5):505 \square 7$.
- 432 33. Yaacoby-Bianu K, Livnat G, Chalmers JD, Shteinberg M. Respiratory healthcare
- 433 professionals' views on long-term recommendations of interventions to prevent acute
- 434 respiratory illnesses after the COVID-19 pandemic. ERJ Open Res. oct
- 435 2022;8(4):00114 2022.
- 436 34. Wu F, Burt J, Chowdhury T, Fitzpatrick R, Martin G, Van Der Scheer JW, et al. Specialty
- 437 COPD care during COVID-19: patient and clinician perspectives on remote delivery.
- 438 BMJ Open Respir Res. janv 2021;8(1):e000817.
- 439 35. Tuppin P, Lesuffleur T, Constantinou P, Atramont A, Coatsaliou C, Ferrat E, et al.
- 440 Underuse of primary healthcare in France during the COVID-19 epidemic in 2020
- 441 according to individual characteristics: a national observational study. BMC Prim Care. 9
 442 août 2022;23(1):200.
- 443 36. Kyriakopoulos C, Gogali A, Exarchos K, Potonos D, Tatsis K, Apollonatou V, et al.
- 444 Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave
- 445 in Greece. Respiration. 2021;100(7):588 93.
- 446 37. Jones AW, King BE, Cumella A, Hopkinson NS, Hurst JR, Holland AE. Use of infection
- 447 control measures in people with chronic lung disease: mixed methods study. ERJ Open
- 448 Res. janv 2024;10(1):00403 \[2023.

- 449 38. Buschulte K, Kabitz HJ, Hagmeyer L, Hammerl P, Esselmann A, Wiederhold C, et al.
- 450 Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD
- 451 registry. Respir Res. 4 janv 2024;25(1):5.
- 452 39. Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic
- 453 pulmonary fibrosis. Eur Respir Rev. 1 sept 2013;22(129):376 81.
- 454 40. Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D, et al.
- 455 Association between pre-existing respiratory disease and its treatment, and severe
- 456 COVID-19: a population cohort study. Lancet Respir Med. août 2021;9(8):909 23.
- 457 41. Tuppin P, De Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health
- 458 insurance information system and the permanent beneficiaries sample. Rev
- 459 DÉpidémiologie Santé Publique. août 2010;58(4):286□90.

461 FIGURE





Figure 1: Monthly hospitalisation rates of lower respiratory tract infection (excluding COVID-19 infection).

Presentation of all hospital admissions for LRTI (A), and according to the presence (B) or absence (C) of a CRD. The observed incidence is depicted by the grey line. The model prediction is presented by the dotted red line, the predicted deterministic trend (regression line) and its 95% confidence intervals by the solid red line.



470 471 Figure 2: Change in LRTI hospitalisation rates during study periods according to the

472 absence or presence of a CRD (A) and according to each category of CRD (B).

473 Period 1 extends from April 2020 to May 2021, period 2 from June 2021 to June 2022 and

474 period 3 from July 2022 to June 2023. Abbreviations: LRTI: Lower respiratory tract infection;

475 CRD: Chronic respiratory disease; CF: cystic fibrosis; ILD: interstitial lung disease; PVD:

476 pulmonary vascular disease; NMD: neuromuscular disease.

477	Table 1: Characteristics of th	e population hos	pitalised for lower respiration	atory tract infection (exclu	ding SARS-CoV-2 infection) in France

478 from July 2013 to June 2023, overall and by study period

	All study period,	Pre-pandemic period,	Period 1,	Period 2,	Period 3,
		July 2013 - March 2020	April 2020 - May 2023	June 2021 - June 2022	July 2022 - June 2023
	N=5,339,989*	N=3,914,800*	N=454,298*	N=442,162*	N=528,729*
Age, years	78 [65-87]	79 [65-87]	76 [64-86]	76 [64-86]	76 [65-86]
Female gender	2,397,253 (44.9%)	1,778,552 (45.4%)	186,733 (41.1%)	192,220 (43.5%)	239,748 (45.3%)
CRD	1,842,925 (34.5%)	1,351,657 (34.5%)	153,779 (33.8%)	153,690 (34.8%)	183,799 (34.7%)
COPD	1,033,930 (19.4%)	771,619 (19.7%)	80,799 (17.8%)	82,931 (18.8%)	98,581 (18.6%)
Asthma	173,729 (3.3%)	129,567 (3.3%)	11,673 (2.6%)	14,155 (3.2%)	18,334 (3.5%)
CF-Bronchiectasis	128,960 (2.4%)	94,155 (2.4%)	11,722 (2.6%)	10,746 (2.4%)	12,337 (2.3%)
ILD	111,601 (2.1%)	80,490 (2.1%)	9,762 (2.1%)	9,793 (2.2%)	11,556 (2.2%)
Thoracic oncology	235,558 (4.4%)	163,889 (4.2%)	24,963 (5.5%)	21,955 (5.0%)	24,751 (4.7%)
PVD	129,683 (2.4%)	91,194 (2.3%)	12,491 (2.7%)	12,098 (2.7%)	13,900 (2.6%)
CRD associated with NMD	8,410 (0.2%)	6,265 (0.2%)	719 (0.2%)	654 (0.1%)	772 (0.1%)
Lung transplantation	12,473 (0.2%)	8,677 (0.2%)	1,310 (0.3%)	1,181 (0.3%)	1,305 (0.2%)
Type of LRTI					
Pneumonia	4,050,133 (75.8%)	2,890,459 (73.8%)	376,531 (82.9%)	357,402 (80.8%)	425,741 (80.5%)
AECOPD	619,367 (11.6%)	481,563 (12.3%)	43,835 (9.6%)	44,293 (10.0%)	49,676 (9.4%)
AEBX	22,644 (0.4%)	16,729 (0.4%)	2,035 (0.4%)	1,890 (0.4%)	1,990 (0.4%)

	All study period,	Pre-pandemic period,	Period 1,	Period 2,	Period 3,
	N=5,339,989*	July 2013 - March 2020 N=3,914,800*	April 2020 - May 2023 N=454,298*	June 2021 - June 2022 N=442,162*	July 2022 - June 2023 N=528,729*
Acute bronchitis	647,845 (12.1%)	526,049 (13.4%)	31,897 (7.0%)	38,577 (8.7%)	51,322 (9.7%)
Admission to the ICU	1,268,087 (23.7%)	922,894 (23.6%)	116,035 (25.5%)	104,909 (23.7%)	124,249 (23.5%)
Direct admission	766,869 (60.5%)	555,100 (60.1%)	70,063 (60.4%)	64,493 (61.5%)	77,213 (62.1%)
Time to ICU admission, days	0 [0-1]	0 [0-1]	0 [0-1]	0 [0-1]	0 [0-1]
Organ support	795,779 (62.8%)	581,481 (63.0%)	72,290 (62.3%)	64,737 (61.7%)	77,271 (62.2%)
SAPSII	33 [20-47]	33 [21-47]	32 [17-47]	32 [18-47]	33 [18-47]
Hospital length of stay, days	9 [5-15]	9 [5-15]	9 [5-16]	9 [4-15]	8 [4-15]
Hospital Death	729,568 (13.7%)	511,725 (13.1%)	74,118 (16.3%)	67,935 (15.4%)	75,790 (14.3%)

479 *Median [Q1-Q3]; n (%)

480 Abbreviations: CRD: chronic respiratory disease; COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; ILD: interstitial lung disease; PVD:

481 pulmonary vascular disease; NDM: neuromuscular disease; LRTI: lower respiratory tract infection; AECOPD: acute exacerbation of COPD; AEBX: acute

482 exacerbation of bronchiectasis; ICU: intensive care unit; SAPSII: simplified acute physiology score